<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663793</url>
  </required_header>
  <id_info>
    <org_study_id>33738-B</org_study_id>
    <secondary_id>U54HD42456-06</secondary_id>
    <secondary_id>K23HD045386</secondary_id>
    <nct_id>NCT00663793</nct_id>
  </id_info>
  <brief_title>ORAL T-6: Oral Androgens in Man-6</brief_title>
  <acronym>ORAL-T-6</acronym>
  <official_title>Oral Androgens in Man-6: Pharmacokinetics of Slow and Fast Release, External Matrix Oral Testosterone Formulations in Normal Men With Experimental Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose a study to determine the single-dose pharmacokinetics of these two novel
      formulations of testosterone in normal men with experimentally induced hypogonadism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an 2-3 month open-label, two week pharmacokinetic study of two novel formulations of
      oral testosterone (T), in normal men whose endogenous T production has been temporarily
      suppressed by the administration of the potent GnRH antagonist Acyline. We will be
      determining the relative pharmacokinetics of six different oral formulations of T in both
      rapid and slow release compared to the immediate release preparation studied previously by
      our group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve-Serum T</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve-serum DHT</measure>
    <time_frame>14-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve-E2</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Contraception</condition>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Oral testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by &quot;immediate release&quot; T 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finasteride plus Oral Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by &quot;immediate release&quot; T 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyline</intervention_name>
    <description>300 mcg/kg</description>
    <arm_group_label>Oral testosterone</arm_group_label>
    <arm_group_label>Finasteride plus Oral Testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>24 hours after acyline administration on Day 2 &quot;immediate release&quot; Testosterone (T) 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
    <arm_group_label>Oral testosterone</arm_group_label>
    <arm_group_label>Finasteride plus Oral Testosterone</arm_group_label>
    <other_name>Oral Testosterone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finasteride</intervention_name>
    <description>1 mg PO once daily [day -2 to day 12) 14 days total</description>
    <arm_group_label>Finasteride plus Oral Testosterone</arm_group_label>
    <other_name>Proscar, Propecia, Fincar, Finpecia, Finax, Finast, Finara, Finalo,</other_name>
    <other_name>Prosteride, Gefina, Appecia, Finasterid IVAX, Finasterid Alternova,</other_name>
    <other_name>Hyplafin, Penester, Finpros, Tectum, Prezepa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males between 18 to 50 years of age in good general health based on normal screening
             evaluation

          -  must agree not to participate in another research drug study during participation

          -  must agree to not donate blood during the study

          -  must be willing to comply with the study protocol and procedures

          -  must agree to use an acceptable form of contraception

          -  agrees to not take medications other than the study drugs for the duration of the
             study

        Exclusion Criteria:

          -  Subject in poor health, determined by medical history physical and lab results

          -  a known history or current use of alcohol, drug or steroid abuse and/or use of more
             than 3 alcohol beverages per day

          -  Participation in a long-term contraceptive study within the past two months

          -  History of bleeding disorders or current use of anti-coagulants

          -  History of sleep apnea and/or major psychiatric disorders
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John K Amory</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr/</url>
    <description>University of Washington</description>
  </link>
  <reference>
    <citation>Plymate SR &quot;Male Hypogonadism&quot; in Principles and Practice of Endocrinology and Metabolism (3rd. Ed). Ed. Kenneth Becker, pp:1125-1150</citation>
  </reference>
  <reference>
    <citation>Amory JK, Bremner WJ. Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. J Clin Endocrinol Metab. 2005 May;90(5):2610-7. Epub 2005 Feb 15.</citation>
    <PMID>15713724</PMID>
  </reference>
  <reference>
    <citation>Amory JK, Page ST, Bremner WJ. Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. J Androl. 2006 Jan-Feb;27(1):72-8.</citation>
    <PMID>16400081</PMID>
  </reference>
  <reference>
    <citation>Herbst KL, Coviello AD, Page S, Amory JK, Anawalt BD, Bremner WJ. A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab. 2004 Dec;89(12):5959-65.</citation>
    <PMID>15579744</PMID>
  </reference>
  <results_reference>
    <citation>Snyder CN, Clark RV, Caricofe RB, Bush MA, Roth MY, Page ST, Bremner WJ, Amory JK. Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism. J Androl. 2010 Nov-Dec;31(6):527-35. doi: 10.2164/jandrol.109.009746. Epub 2010 Apr 8.</citation>
    <PMID>20378927</PMID>
  </results_reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <results_first_submitted>June 25, 2010</results_first_submitted>
  <results_first_submitted_qc>December 27, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 24, 2011</results_first_posted>
  <last_update_submitted>December 27, 2010</last_update_submitted>
  <last_update_submitted_qc>December 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>John K Amory, MD, MPH</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>Male Contraception</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>Testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Finasteride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited through news media (newspaper, website) and college campus bulletin boards in Seattle WA, between April 2008-March 2009.</recruitment_details>
      <pre_assignment_details>19 participants recruited; 19 screened, 2 excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Testosterone Only</title>
          <description>(Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by &quot;immediate release&quot; T 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
        </group>
        <group group_id="P2">
          <title>Testosterone Plus Finasteride</title>
          <description>(Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by &quot;immediate release&quot; T 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Testosterone Only</title>
          <description>(Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by &quot;immediate release&quot; T 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
        </group>
        <group group_id="B2">
          <title>Testosterone Plus Finasteride</title>
          <description>(Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by &quot;immediate release&quot; T 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="4"/>
                    <measurement group_id="B2" value="28" spread="8"/>
                    <measurement group_id="B3" value="27" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estradiol</title>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.1" spread="16.1"/>
                    <measurement group_id="B2" value="114" spread="54"/>
                    <measurement group_id="B3" value="92.0" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178" spread="5"/>
                    <measurement group_id="B2" value="179" spread="7"/>
                    <measurement group_id="B3" value="178.5" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex Hormone Binding Globulin (SHBG)</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="12.8"/>
                    <measurement group_id="B2" value="32.5" spread="19.6"/>
                    <measurement group_id="B3" value="34" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Testosterone (T)</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" spread="2.5"/>
                    <measurement group_id="B2" value="16.8" spread="8.9"/>
                    <measurement group_id="B3" value="15.65" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83" spread="18"/>
                    <measurement group_id="B2" value="89" spread="22"/>
                    <measurement group_id="B3" value="86" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve-Serum T</title>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Only</title>
            <description>(Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by &quot;immediate release&quot; T 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Finasteride</title>
            <description>(Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by &quot;immediate release&quot; T 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve-Serum T</title>
          <units>nmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>external matrix 'immediate' release</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143" spread="47"/>
                    <measurement group_id="O2" value="198" spread="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>external matrix 'fast' release</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" spread="44"/>
                    <measurement group_id="O2" value="384" spread="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>external matrix 'slow' release</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162" spread="60"/>
                    <measurement group_id="O2" value="237" spread="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A sample size of 8 per group was estimated to confer an 80% power to detect a 40% difference in testosterone AUC with a standard deviation of 20% at an alpha of 0.05</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon sign-rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve-serum DHT</title>
        <time_frame>14-days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Only</title>
            <description>(Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by &quot;immediate release&quot; T 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Finasteride</title>
            <description>(Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by &quot;immediate release&quot; T 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve-serum DHT</title>
          <units>nmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>external matrix 'immediate' release</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="13"/>
                    <measurement group_id="O2" value="23" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>external matrix 'fast' release</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="21"/>
                    <measurement group_id="O2" value="26" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>external matrix 'slow' release</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="16"/>
                    <measurement group_id="O2" value="26" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No power calculation was performed for this pilot study.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon sign-rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve-E2</title>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Only</title>
            <description>(Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by &quot;immediate release&quot; T 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Finasteride</title>
            <description>(Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by &quot;immediate release&quot; T 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve-E2</title>
          <units>nmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>external matrix 'immediate' release</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1812" spread="405"/>
                    <measurement group_id="O2" value="2241" spread="783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>external matrix 'fast' release</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1961" spread="528"/>
                    <measurement group_id="O2" value="2002" spread="861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>external matrix 'slow' release</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1944" spread="652"/>
                    <measurement group_id="O2" value="3129" spread="1574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Area-under-the-curve for serum estradiol</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No power calculation was performed for this pilot study</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Testosterone Only</title>
          <description>(Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by &quot;immediate release&quot; T 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
        </group>
        <group group_id="E2">
          <title>Testosterone Plus Finasteride</title>
          <description>(Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by &quot;immediate release&quot; T 300 mg po once (as a control), followed 24 hours later (Day 3) by &quot;external matrix fast release&quot; T 300 mg once, followed 24 hours later (Day 4) by &quot;external matrix slow release&quot; T 300 mg once, followed 96 hours later (Day 8) by &quot;immediate release&quot; T 600 mg, followed 24 hours later (Day 9) by &quot;external matrix fast release&quot; T 600 mg po once, followed 48 hours later (Day 11) by &quot;external matrix slow release&quot; T 600 mg once.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Libido</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John K Amory, MD, MPH</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-616-1727</phone>
      <email>jamory@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

